Gregory M. Heestand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gregory M. Heestand has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Albert C. Koong
Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1 shared publication - Alison Figueroa Almeda
Division of Oncology Department of Medicine Stanford University School of Medicine 94305 Stanford CA United States
1 shared publication Bryce Moulton
Precision Genomics, Intermountain Healthcare, St. George, Utah
1 shared publicationChristina M. Wood-Bouwens
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California
1 shared publication- Daniel T. Chang
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48103, USA
1 shared publication - David Benjamin Shultz
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
1 shared publication
Latest Publications
- 1 February 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (2) , 247-261
Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR
- 1 February 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (2) , 247-261
Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR
- Open Access
- 25 January 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (1) , e0147995
A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3
NCIC Clinical Trials Group PA.3 was a randomized control trial that demonstrated improved overall survival (OS) in patients receiving erlotinib in addition to gemcitabine for locally advanced or metastatic pancreatic cancer. Prior to therapy, patients had plasma samples drawn for future study. We sought to identify biomarkers within these samples. Using the proximity ligation assay (PLA), a probe panel was built from commercially available antibodies for 35 key proteins selected from a global genetic analysis of pancreatic cancers, and used to quantify protein levels in 20 uL of patient plasma. To determine if any of these proteins levels independently associated with OS, univariate and mulitbaraible Cox models were used. In addition, we examined the associations between biomarker expression and disease stage at diagnosis using Fisher's exact test. The correlation between Erlotinib sensitivity and each biomarkers was assessed using a test of interaction between treatment and biomarker. Of the 569 eligible patients, 480 had samples available for study. Samples were randomly allocated into training (251) and validation sets (229). Among all patients, elevated levels of interleukin-8 (IL-8), carcinoembryonic antigen (CEA), hypoxia-inducible factor 1-alpha (HIF-1 alpha), and interleukin-6 were independently associated with lower OS, while IL-8, CEA, platelet-derived growth factor receptor alpha and mucin-1 were associated with metastatic disease. Patients with elevated levels of receptor tyrosine-protein kinase erbB-2 (HER2) expression had improved OS when treated with erlotinib compared to placebo. In conclusion, PLA is a powerful tool for identifying biomarkers from archived, small volume serum samples. These data may be useful to stratify patient outcomes regardless of therapeutic intervention. ClinicalTrials.gov NCT00040183
- 25 January 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (1) , e0147995
Open AccessA Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3
NCIC Clinical Trials Group PA.3 was a randomized control trial that demonstrated improved overall survival (OS) in patients receiving erlotinib in addition to gemcitabine for locally advanced or metastatic pancreatic cancer. Prior to therapy, patients had plasma samples drawn for future study. We sought to identify biomarkers within these samples. Using the proximity ligation assay (PLA), a probe panel was built from commercially available antibodies for 35 key proteins selected from a global genetic analysis of pancreatic cancers, and used to quantify protein levels in 20 uL of patient plasma. To determine if any of these proteins levels independently associated with OS, univariate and mulitbaraible Cox models were used. In addition, we examined the associations between biomarker expression and disease stage at diagnosis using Fisher's exact test. The correlation between Erlotinib sensitivity and each biomarkers was assessed using a test of interaction between treatment and biomarker. Of the 569 eligible patients, 480 had samples available for study. Samples were randomly allocated into training (251) and validation sets (229). Among all patients, elevated levels of interleukin-8 (IL-8), carcinoembryonic antigen (CEA), hypoxia-inducible factor 1-alpha (HIF-1 alpha), and interleukin-6 were independently associated with lower OS, while IL-8, CEA, platelet-derived growth factor receptor alpha and mucin-1 were associated with metastatic disease. Patients with elevated levels of receptor tyrosine-protein kinase erbB-2 (HER2) expression had improved OS when treated with erlotinib compared to placebo. In conclusion, PLA is a powerful tool for identifying biomarkers from archived, small volume serum samples. These data may be useful to stratify patient outcomes regardless of therapeutic intervention. ClinicalTrials.gov NCT00040183